Controlled Anti-platelet medical therapy based on rapid CYP2C19 gene evaluation in Acute myocardial infarction

INTERVENTION: Non‐carriers of CYP2C19 reduced function allele with standard dual anti‐platelet therapy(asprin 100mg + clopidogrel 75mg) Carriers of CYP2C19 reduced function allele with standard dual anti‐platelet therapy (asprin 100mg + clopidogrel 75mg) Carriers of CYP2C19 reduced function allele with triplet antiplatelet therapy (asprin 100mg + clopidogrel 75mg + cilostazol 200mg) CONDITION: Acute myocardial infarction PRIMARY OUTCOME: 1.The frequency of CYP2C19 *2, *3, and *17 polymorphism in acute myocardial infarction.; 2.Difference of several change in the residual platelet aggregation and the biomarkers for blood coagulation and cardiac biomarkers. SECONDARY OUTCOME: Composite cardiovascular events(cardiac death, fatal and non fatal stroke, non‐fatal myocardial infarction, ; hospitalization for cardiovascular event, percutaneous coronary intervention or coronary artery bypass graft, hospitalization for heart failure, deep vein thrombosis, pulmonary thromboembolism, hospitalization for peripheral arterial disease, hemorrhagic complication) INCLUSION CRITERIA: Patients with ST elevation myocardial infarction and non ST elevation myocrdial ingarction who underwent emergent percutaneous coronary intervention.